https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-adrenocortical-carcinoma-adrenal-cortex-cancer-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-216106&utm_campaign=recommended-articles-pi
Pembrolizumab is under clinical development by Merck and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer).
adrenal cortex canceradrenocortical carcinomapembrolizumabmercklikelihood